Tema Etfs LLC Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)

Tema Etfs LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,223 shares of the company’s stock, valued at approximately $280,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics in the fourth quarter valued at about $139,000. Meeder Asset Management Inc. bought a new position in shares of Janux Therapeutics in the fourth quarter valued at about $159,000. Tower Research Capital LLC TRC raised its position in shares of Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after purchasing an additional 3,436 shares during the period. Finally, Brevan Howard Capital Management LP bought a new position in shares of Janux Therapeutics in the fourth quarter valued at about $221,000. 75.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on JANX shares. Wedbush reissued an “outperform” rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank reduced their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Trading Up 4.3%

Shares of NASDAQ JANX opened at $24.28 on Monday. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -20.75 and a beta of 3.24. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71. The stock has a 50-day moving average price of $28.66 and a two-hundred day moving average price of $40.54.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $30.00, for a total value of $100,020.00. Following the completion of the transaction, the insider now owns 82,139 shares of the company’s stock, valued at $2,464,170. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is currently owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.